Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Innovations in Cell Therapy for Relapsed and Refractory Multiple Myeloma with Dr. Chris Heery Arcellx TRANSCRIPT
Download PDFSep 27, 2024
Dr. Chris Heery is Chief Medical Officer at Arcellx, a company focusing on developing anito-cel, a significant advancement in CAR-T cell therapy, to treat relapsed and refractory multiple myeloma (rrMM). Multiple myeloma is a rare type of blood cancer that affects plasma cells in the bone marrow and has few treatment options. Arcellx is showing promising data from clinical trials with patients with rrMM who have failed prior therapies and have received Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations from the FDA for anito-cel.
Chris explains, "The company was founded based on an idea that you could take a novel protein structure and modify it to be able to bind to targets on the surface of cancer cells. And over many years of work, the founders were able to demonstrate that that was possible. Over the last three or four years, Arcellx has focused more on taking what were some of those early ideas and turning them into a product that can help patients. For these last three or four years, most of our focus has been around the lead asset that we call anito-cel that treats multiple myeloma and trying to get that product through the approval process to be able to be a commercial product that can be used for patients both in the United States and the rest of the world."
"When a patient is diagnosed with multiple myeloma, in general, most patients are older. The median age of diagnosis of multiple myeloma is around 70 years old, and those plasma cells can cause damage to the normal bone marrow by crowding out the normal bone marrow."
"They can also make a lot of the protein that a normal plasma cell would make. By making a lot of that protein, those proteins can cause deposition and damage into other tissues. So, patients can arrive at the clinic with a variety of different symptoms that have to do with either decreased bone marrow activity, decreased number of normal cell populations in their blood, or damage to things like their kidneys or other end organs that you need for normal human function."
#Arcellx #CellTherapy #CARTTherapy #RRMM #MultipleMyeloma #BloodCancer #Cancer #RareDisease
